NPS Pharmaceuticals (NPSP): Q1 EPS of -$0.12 misses by $0.01. Revenue of $22.2M (-3% Y/Y) misses...

This news story has 2 comments:

Register or Login to rate comments »

SteveBoulay Comment (1)
 
This stock should be a double or more over the next 6-12 months on GATTEX approval, NATPARA approval and return of Sensipar Royatlies starting in 2013 mid-year. Assumsing a minimum of 5 years patent protection Sensipar should net 500m to the bottom line for NPSP
4 May 2012, 04:53 AM Reply Like

Christopher Nassar Comments (6)
 
Still a very good stock to hold long-term.
4 May 2012, 08:13 AM Reply Like